NervGen Pharma, a clinical-stage biopharmaceutical company focused on neuroreparative treatments for spinal cord injuries, announced its participation in two upcoming investor events: the H.C. Wainwright "HCW@Home" series on April 15, 2026, and the Bloom Burton & Co. Healthcare Investor Conference on April 21-22, 2026. CEO Dr. Adam Rogers and the leadership team will present updates on their lead drug candidate NVG-291, which targets chronic tetraplegia and has received FDA Fast Track and EMA Orphan Drug designations. These presentations will provide investors with insights into the company's progress and future plans, including advancing NVG-291 towards Phase 3 trials. Live webcasts will be available for both events.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...
Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...
Zcash (ZEC) has gained over 16% in the past week, rallying from lows near $368 to around $552 following an 11% jump in one session. This surge is driven by anticipation of the Ironwood shielded pool upgrade expected around July 28, which addresses a ...
Greenwich LifeSciences is developing GLSI-100, an immunotherapy targeting HER2-positive breast cancer, currently in Phase 3 trials. The drug showed a 70-80% reduction in cancer recurrence in Phase 2b, outperforming existing treatments with no serious...
